Search for: "PRECISION STANDARD V US"
Results 4121 - 4140
of 4,555
Sort by Relevance
|
Sort by Date
23 Sep 2009, 4:00 am
V. [read post]
22 Sep 2009, 9:43 pm
A large part of the decision focuses on the precise warranty in question, and the precise nature of the charges in question. [read post]
21 Sep 2009, 2:04 pm
In Schroer v. [read post]
18 Sep 2009, 7:23 am
The standard of review is therefore reasonableness [read post]
11 Sep 2009, 6:31 pm
In a standard running royalty [read post]
11 Sep 2009, 2:47 am
NidekThe first of these was Perez v. [read post]
10 Sep 2009, 1:58 am
The case was patterned on a highly controversial one, Commonwealth v. [read post]
8 Sep 2009, 2:44 am
There is no mathematically precise test in deciding these cases, the Court of Appeals reminds us. [read post]
6 Sep 2009, 11:46 pm
Cir. 1993).While that standard is easy to state, it has not always proved easy to apply. [read post]
4 Sep 2009, 6:32 pm
Dickinson v. [read post]
3 Sep 2009, 8:25 pm
In other words, "the earlier application need not describe the claimed subject matter in precisely the same terms as found in the claims at issue. [read post]
3 Sep 2009, 9:23 am
CR v. [read post]
3 Sep 2009, 1:40 am
Buntzman and Johnson v. [read post]
2 Sep 2009, 10:40 am
Here's some good stuff from Judge Canby on that topic:"We confess considerable uneasiness in applying this standard to the acceptance of campaign contributions because, in our flawed but nearly universal system of private campaign financing, large contributions are commonly given in expectation of favorable official action. . . . [read post]
26 Aug 2009, 6:05 pm
By Nancy Berner In a positive development for employers and their defense counsel alike, the Fourth District Court of Appeals upheld the San Diego trial court’s denial of class certification in Ali v. [read post]
26 Aug 2009, 9:35 am
" Lieb v. [read post]
26 Aug 2009, 9:35 am
" Lieb v. [read post]
26 Aug 2009, 9:35 am
" Lieb v. [read post]
26 Aug 2009, 6:12 am
(Korea IP Law Blog) US: Senate Agriculture/FDA Appropriations Bill amendment seeks to streamline development and regulation of products for rare and neglected diseases (FDA Law Blog) US: Professor Grabowski’s economic analysis of data exclusivity for follow-on biologic drugs (Patent Docs) US: Follow-on biologics news briefs: President Obama wants to speed up introduction of generic drugs; biosimilars pose ‘limited threat’; Amgen CEO says… [read post]
23 Aug 2009, 3:32 pm
In this case, the trial court did precisely what we have long said it could. [read post]
